Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

Inclusion Criteria: * Histologically documented prostate, breast, or non-small cell lung cancer (NSCLC) * Metastatic disease in bone only (patients with visceral disease, cutaneous disease or malignant lymph nodes \> 3 cm in largest diameter are not eligible) * Documented disease progression (1 or more new bone lesion or enlargement of existing bone lesion, identified by Tc-99m bone scintigraphy or CT scan, magnetic resonance imaging \[MRI\], fludeoxyglucose F-18 \[FDG\] PET CT scan or PSMA PET CT scan) * Must have progression on at least one line of standard of care systemic therapy. There are no maximum number of prior therapies * Patients with prostate cancer * Patients with prostate adenocarcinoma, their disease must be characterized as: must have prior bilateral orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (\< 50 ng/dL or \< 1.7 nmol/L) * Serum PSA progression, defined as two consecutive increases in PSA over a previous reference value, each measurement at least one week apart or, PSA progression ≥ 25% after 12 weeks of current standard of care (SOC) therapy (Scher et al., 2016) * Patients must have a baseline positive PSMA-PET scan. Patients must have progressed on at least one line of hormone therapy: Androgen receptor signaling inhibitors (ARSIs) therapy such as enzalutamide, apalutamide, darolutamide, or androgen synthesis blockers (abiraterone acetate). There are no minimum number of prior hormone therapies …